Fierce Pharma

Pfizer’s victory in delaying Vyndamax generics is mixed bag for BridgeBio: analysts

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...
Fierce Pharma

Pfizer settles with 2 generic Vyndamax makers in latest twist to ATTR market: analysts

As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...

BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore

BridgeBio Pharma, Inc. remains a Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics. Learn more ...

BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update)

BridgeBio (BBIO) rose 6.6% after a court filing disclosed a settlement in a generic patent case over Pfizer's (PFE) Vyndamax ...
Hosted on MSN

Pfizer settles to delay Vyndamax generics until 2031

Pfizer has reached settlements with three generic drugmakers, pushing back U.S. market entry of Vyndamax copies until mid-2031, pending other litigation. The move preserves billions in annual revenue ...
BioSpace

Pfizer settles with generic drugmakers to protect blockbuster drug until 2031

The settlements delay the entry of generic copies of Pfizer’s Vyndamax by almost three years, stabilizing sales of a drug ...